Showing 1961-1970 of 3223 results for "".
- Alcon to Launch TOTAL30 as the First Monthly Replacement, Water Gradient Contact Lenshttps://modernod.com/news/alcon-to-launch-total30-as-the-first-monthly-replacement-water-gradient-contact-lens/2479449/Alcon announced plans to launch TOTAL30, the first-and-only monthly replacement, water gradient lens. Using Alcon’s proprietary water gradient material first introduced with DAILIES TOTAL1 contact lenses, TOTAL30 delivers a premium wearing experience for reusable contact lens wearers, according t
- Aldeyra Therapeutics Receives Orphan Drug Designation from the FDA for ADX-2191 to Treat Retinitis Pigmentosahttps://modernod.com/news/aldeyra-therapeutics-receives-orphan-drug-designation-from-the-fda-for-adx-2191-to-treat-retinitis-pigmentosa/2479434/Aldeyra Therapeutics announced that the FDA has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP). Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular replication and activation. In
- Allegro Announces Positive Results of Vehicle-Controlled Ex-US Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/allegro-announces-positive-results-of-vehicle-controlled-ex-us-phase-2-trial-of-alg-1007-for-the-treatment-of-dry-eye-disease/2479410/Allegro Ophthalmics announced that all primary and secondary endpoints of an ex-US vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met. The results were presented by Eric D. Donnenfeld, MD, at the 2021 American Society of Cataract and Refractive S
- Alcon Reinforces Strength of Ophthalmology Portfolio With Surgical Device Scientific Presence at ASCRShttps://modernod.com/news/alcon-reinforces-strength-of-ophthalmology-portfolio-with-surgical-device-scientific-presence-at-ascrs/2479398/Alcon will present a breadth of data during the American Society of Cataract and Refractive Surgery (ASCRS) 2021 annual meeting, taking place July 23-27 in Las Vegas. More than 60 abstracts featuring Alcon ophthalmic products and equipment will be presented. The full abstract book, registration l
- Alcon to Share New Data and Live Booth Presentations at ASCRShttps://modernod.com/news/alcon-to-share-new-data-and-live-booth-presentations-at-ascrs/2479391/Alcon will have approximately 70 abstracts highlighting the benefits of the Alcon Cataract and Refractive suite. A few highlights of the Alcon data include: Robust data demonstrates extremely high level of patient satisfaction and increased spectacle independence for market-leading <
- Allergan to Present New Data from its Eye Care Portfolio at the 2021 ASCRShttps://modernod.com/news/allergan-to-present-new-data-from-its-eye-care-portfolio-at-the-2021-ascrs/2479386/Allergan announced that it will present new data from its leading portfolio of eye care medicines at the 2021 ASCRS (American Society for Cataract and Refractive Surgery) annual meeting being held July 23-27 in Las Vegas. Presentations will include new data on AGN-190584 (pilocarpine 1.25%), an i
- Allegro Ophthalmics to Present the Results of ALG-1007 Ex-U.S. Phase 2 Clinical Trial for Dry Eye Disease at ASCRShttps://modernod.com/news/allegro-ophthalmics-to-present-the-results-of-alg-1007-ex-u-s-phase-2-clinical-trial-for-dry-eye-disease-at-ascrs/2479379/Allegro Ophthalmics announced that the results of the company’s second ALG-1007 ex-U.S. clinical trial for the treatment of dry eye disease (DED) will be presented during the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS ASOA) an
- FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 for the Treatment of Stargardt Diseasehttps://modernod.com/news/fda-grants-alkeus-pharmaceuticals-breakthrough-therapy-designation-for-alk-001-c20-d3-vitamin-a-for-the-treatment-of-stargardt-disease/2479374/Alkeus Pharmaceuticals announced that the FDA has granted Breakthrough Therapy Designation to ALK-001 for the treatment of Stargardt Disease. ALK-001 (C20-D3-vitamin A) is a chemically-modified form of vitamin A developed to treat multiple retinal degenerati
- EyePoint Pharmaceuticals Reports Positive 30-Day Safety Results for All Cohorts From DAVIO Trial of EYP-1901 for Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-reports-positive-30-day-safety-results-for-all-cohorts-from-the-davio-trial-of-eyp-1901-for-wet-amd/2479344/EyePoint Pharmaceuticals announced positive safety results from its phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (AMD). All dose cohorts have reached at least 30-day post-dosing foll
- William J. Link, PhD, Named Chairman of Allegro Ophthalmics’ Board of Directorshttps://modernod.com/news/william-j-link-phd-named-chairman-of-allegro-ophthalmics-board-of-directors/2479313/Allegro Ophthalmics announced that William J. Link, PhD, has been appointed chairman by the company’s board of directors and that Stephanie Yee was named vice president of finance. “I am thrilled that Bill has agreed to serve as our board chairman and pleased to promote Stephanie as VP of